Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals has opened its security purchase plan as part of a broader capital raising, offering eligible shareholders up to A$30,000 of new shares at A$0.06 each. Participants will also receive one option per new share, exercisable at A$0.06 and expiring on 31 January 2027, with the SPP underwritten to A$5 million and the ability to accept oversubscriptions.
The offer, made under a newly lodged prospectus, is subject to shareholder approval at a general meeting on 1 April 2026 and is scheduled to close on 13 April 2026. The capital injection is intended to strengthen Botanix’s financial position as it advances commercialisation of its dermatology portfolio, following FDA approval of Sofdra for primary axillary hyperhidrosis.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals is a commercial dermatology company based in Philadelphia and Phoenix, focused on developing and marketing treatments for skin conditions. The company has secured FDA approval for Sofdra, the first and only new chemical entity approved to treat primary axillary hyperhidrosis, targeting patients who previously had limited therapeutic options.
Average Trading Volume: 9,220,497
Technical Sentiment Signal: Sell
Current Market Cap: A$119.8M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.